Close X
my esmo
 
Username: Password:
Remember me!


Forgot your Password? Create an account

Use of the ESMO services is subject to the Terms & Conditions and constitutes your agreement to abide by these.

Close X
my esmo
 
Username: Password:
Remember me!


Forgot your Password? Create an account

Use of the ESMO services is subject to the Terms & Conditions and constitutes your agreement to abide by these.

4th IMPAKT Breast Cancer Conference, Brussels, Belgium, 3-5 May 2012

IMPAKT - Improving care and knowledge through translational research

A unique Breast Cancer Conference that bridges the gap between research and clinic while also providing the right environment for young professionals to network with and access the knowledge of their senior counterparts.

Meeting resources

Access the Webcast See the Abstract Book online


Interview with Prof Reis-Filho on molecular pathology at the basis of personalized medicine
Prof Reis-Filho explores the latest high throughput technology results in molecular pathology to improve treatment for cancer patients


Interview with Dr Angelo Di Leo on potential new promising approaches to attack the different subtypes of triple negative breast cancer
Dr Di Leo explains why triple negative breast cancer is a difficult heterogeneous disease and which are potential new promising appraches


Interview with Prof Swanton on the challenges posed by intratumor heterogeneity
Prof Swanton offers a clear-cut picture of challeges and opportunities offered by improved knowledge of intratumor heterogeneity
 
IMPAKT focuses on translational research in breast cancer and on innovative ways of developing new agents. It is a valuable meeting which brings together pre-clinical and clinical researchers from Academia and Industry, junior and senior oncologists and facilitates the role of mentor and the importance of sharing knowledge to improve careers. The rapid translation of biologically-based laboratory discoveries into daily clinical practice is important, but equally important is the trip back from the clinic to the laboratory, to further explore and explain clinically observed tumor biology and behavior.